mps1

Mps1-IN-1 is a potent, selective, and ATP-competitive inhibitor of Mps1 kinase (IC50: 367 nM).

Mps1-IN-1 dihydrochloride, a potent ATP-competitive inhibitor of Mps1 kinase, exhibits an IC50 of 367 nM. It effectively inhibits the activity of Mps1 mitotic kinase and disrupts spindle assembly checkpoint (SAC) function, thereby reducing the viability of both cancerous and 'normal' cells.

Mps1-IN-3 is an effective and selective inhibitor of MPS1 kinase (IC50: 50 nM).

MPS1/TTK inhibitor is an inhibitor of monopolar spindle 1 (MPS1/TTK; IC50 = 5.8 nM), a kinase involved in mitotic spindle checkpoint signaling that is overexpressed in certain cancerous tumors. It inhibits MPS1 phosphorylation of kinetochore scaffold 1 (KNL1) and increases the rate of mitosis and the number of cells entering anaphase within 15 minutes, indicating MPS1 checkpoint inhibition, when used at a concentration of 100 nM. MPS1/TTK inhibitor (50 and 100 nM) increases the number of missegregated chromosomes, with an increased number of errors at 100 nM compared with 50 nM. It also inhibits colony formation of DLD1, HCT116, and U2OS cells (IC50s = 24.6, 20.1, and 20.6 nM, respectively).

Mps1-IN-8, a Mps1 inhibitor, can be utilized in the study of various tumors [1].

Mps1-IN-6 (Compound 9) is a highly effective Mps1 inhibitor with an IC50 value of 6.4 nM and exhibits significant anti-proliferation and anti-tumor effects on breast cancer cells.

Mps1-IN-5 is a potent, orally active Mps1 inhibitor exhibiting an IC50 of 29 nM, known for triggering apoptosis and G2 M phase cell cycle arrest. This compound demonstrates antiproliferative and anti-tumor effects by inhibiting Mps1 phosphorylation and inducing DNA damage [1].

Mps1-IN-6, a potent Mps1 inhibitor, demonstrates antiproliferative and antitumor activities with an IC50 of 2.596 nM [1].

TC-Mps1-12 is an effective and selective inhibitor of monopolar spindle 1 (IC50: 6.4 nM) .

Mps1-IN-3 hydrochloride is a potent and selective inhibitor of Mps1 (IC50: 50 nM) that exhibits inhibitory effects on the proliferation of glioblastoma cells and effectively sensitizes glioblastomas to vincristine in an in situ xenograft tumor model.

Mps1-IN-2 is a potent, selective, and ATP-competitive inhibitor of both Mps1 and Plk1.

Mps1-IN-4 is a compound that selectively inhibits Monopolar spindle 1 (Mps1), exhibiting antiproliferative properties useful in cancer research.

CCT-271850 is an inhibitor of the spindle checkpoint function of Monospindle 1.

BAY 1217389 is an effective and selective inhibitor of the monopolar spindle 1 (MPS1) kinase (IC50<10 nM).

CFI-402257 is a selective inhibitor of Mps1/TTK kinase (Mps1 Ki = 0.09 nM; EC50 = 6.5 nM)and can be used in studies about hepatocellular carcinoma diseases.

Empesertib (BAY 1161909) is an orally bioavailable and selective inhibitor Mps1(IC50 < 1 nM), with potential antineoplastic activity.

AZ3146 is a selective Mps1 inhibitor with IC50 of ~35 nM.

MPI-0479605 is an ATP competitive and selective inhibitor.

BOS-172722 is an inhibitor of the monopolar spindle 1 (MPS1) checkpoint with an IC50 of 2 nM.

DW532 is one of simplified analogues of hematoxylin that has shown broad-spectrum inhibition on tyrosine kinases and in vitro anti-cancer activities. DW532 inhibited EGFR and VEGFR2 in vitro kinase activity (the IC50 values were 4.9 and 5.5 μmol/L, respectively), and suppressed their downstream signaling. DW532 dose-dependently inhibited tubulin polymerization via direct binding to tubulin, thus disrupting the mitotic spindle assembly and leading to abnormal cell division. In a panel of human cancer cells, DW532 (1 and 10 μmol/L) induced G2/M phase arrest and cell apoptosis, which subsequently resulted in cytotoxicity. Knockdown of BubR1 or Mps1, the two core proteins of the spindle assembly checkpoint dramatically decreased DW532-induced cell cycle arrest in MDA-MB-468 cells. Moreover, treatment with DW532 potently and dose-dependently suppressed angiogenesis in vitro and in vivo. ( Acta Pharmacol Sin. 2014 Jul;35(7):916-28.)

CFI-402257 hydrochloride, a highly selective and orally bioavailable inhibitor targeting TTK/Mps1, demonstrates an in vitro IC50 value of 1.7 nM against TTK. This compound exhibits anti-cancer activity [1].

CCT251455 is an inhibitor of mitotic kinase monopolar spindle 1 (MPS1; IC50: 3 nM).

RMS-07, a covalent inhibitor of Monopolar Spindle Kinase 1 (MPS1/TTK), exhibits a potent inhibitory concentration (IC50) of 13.1 nM. Specifically, it targets a poorly conserved cysteine located in the hinge region of the kinase.

Rac-CCT-250863, a potent Nek2 inhibitor, exhibits selectivity for Nek2 over PLK1, MPS1, Cdk2 and Aurora A.

NMS-P715 is a selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).

Mps-BAY2b is a novel MPS1 inhibitor.